New Strategy for the Detection and Treatment of Helicobacter Pylori Infections in Primary Care Guided by a Non-invasive PCR in Stool
NCT05495854 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 246
Last updated 2026-04-30
Summary
In France, every year 1 million people are explored for Helicobacter pylori infection and 200,000 receive eradication treatment. Faced with the high prevalence of Hp resistance to antibiotics, the Haute Autorité de Santé (HAS) has recommended since 2017 a treatment strategy guided by the results of bacteriological tests (culture and antibiogram and / or PCR) carried out from gastric biopsies. Guided therapy is more effective, cheaper, and better tolerated than empiric therapy (it includes fewer antibiotics). But the guided treatment is not used despite the recommendations because of the invasive nature of the endoscopy, the difficulty of culture and the non-reimbursement of the PCR. A new non-invasive test by real-time PCR performed on the stools of patients makes it possible to detect the Hp infection and its sensitivity to clarithromycin and therefore to guide the treatment with excellent performance as we have been able to demonstrate during a study including 1200 patients (Pichon et al J Clin Microbiol 2020). These characteristics allow this test to be used in primary care but has to be evaluated.
Conditions
- Helicobacter Pylori Infection
Interventions
- DIAGNOSTIC_TEST
-
PCR test in the stool
Patients randomized to the "new strategy" arm will receive a prescription for an Hp serology and a stool self-collection kit . Only the result of the PCR test in the stool will be considered for this arm. A positive test will determine Hp infection and the indication for treatment.
Sponsors & Collaborators
-
Poitiers University Hospital
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-02-03
- Primary Completion
- 2025-10-20
- Completion
- 2025-10-20
Countries
- France
Study Locations
More Related Trials
-
Helicobacter Pylori Antibiotic Susceptibility Testing of Korea
NCT02961296 ·Status: UNKNOWN
-
Helicobacter Pylori Resistance
NCT05019586 ·Status: COMPLETED
-
Prevalence and Trends of Antimicrobial Resistance of Helicobacter Pylori in Korea
NCT05247112 ·Status: RECRUITING
-
French Pediatric Helicobacter Pylori Observatory
NCT03541876 ·Status: UNKNOWN
-
Helicobacter Pylori Eradication Study
NCT03130452 ·Status: COMPLETED ·Phase: PHASE4
-
Therapeutic Trial Comparing Triple Therapy Guided by the PCR Detection of Clarithromycin Resistance vs Empiric Concomitant Quadruple Therapy for Helicobacter Pylori Infection
NCT02576236 ·Status: UNKNOWN ·Phase: NA
-
A Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure
NCT05493644 ·Status: UNKNOWN
-
High-Dose Dual Therapy for H. Pylori Eradication (RETRO-HP Study)
NCT07121205 ·Status: COMPLETED
-
Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection
NCT02934048 ·Status: UNKNOWN ·Phase: PHASE4
-
Genotypic Resistance Guided Versus Susceptibility Testing Guided Therapy for the First-line Eradication of H. Pylori
NCT03556254 ·Status: UNKNOWN ·Phase: PHASE4
-
Prospective Study : Helicobacter Pylori Eradication Therapy in Accordance With Past Antibiotics Use
NCT01938534 ·Status: UNKNOWN ·Phase: PHASE4
-
The Study of the Antimicrobial Resistance of Helicobacter Pylori in Shandong Province
NCT04029415 ·Status: UNKNOWN
-
Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.
NCT04107194 ·Status: UNKNOWN ·Phase: PHASE3
-
Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment
NCT02988089 ·Status: UNKNOWN ·Phase: PHASE4
-
A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile
NCT05926804 ·Status: RECRUITING ·Phase: NA
-
Efficacy of Acetilcysteine in 'Rescue' Therapy for Helicobacter Pylori Infection. Pilot Study
NCT00985608 ·Status: UNKNOWN ·Phase: PHASE2
-
A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection
NCT02689583 ·Status: UNKNOWN ·Phase: NA
-
Efficacies of Susceptibility-guided vs Empiric Therapy for Rescue Treatment of Helicobacter Pylori Infection
NCT05332444 ·Status: RECRUITING ·Phase: PHASE4
-
Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment
NCT03139253 ·Status: UNKNOWN ·Phase: PHASE4
-
The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori
NCT02349685 ·Status: COMPLETED ·Phase: NA
-
Community-based Helicobacter Pylori Eradication
NCT00155389 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori
NCT06751121 ·Status: COMPLETED ·Phase: PHASE3
-
A Multi-center Study for Eradication of Refractory Helicobacter Pylori
NCT02741414 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection
NCT05133193 ·Status: UNKNOWN ·Phase: NA
-
Helicobacter Pylori First-line Treatment Containing Tetracycline in Patients Allergic to Penicillin
NCT05129176 ·Status: UNKNOWN ·Phase: PHASE4